Last update 24 Dec 2024

Rivaroxaban

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Rivaroxaban (JAN/USAN/INN), AST-8294, BAY 59 7939
+ [9]
Target
Mechanism
factor Xa inhibitors(Factor Xa inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationFast Track (US), Priority Review (CN)
Login to view timeline

Structure

Molecular FormulaC19H18ClN3O5S
InChIKeyKGFYHTZWPPHNLQ-AWEZNQCLSA-N
CAS Registry366789-02-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Thromboembolism
JP
24 Nov 2023
Thrombosis
US
20 Dec 2021
Atherosclerosis
EU
12 Nov 2021
Atherosclerosis
IS
12 Nov 2021
Atherosclerosis
LI
12 Nov 2021
Atherosclerosis
NO
12 Nov 2021
Atrial Fibrillation
CN
31 Mar 2009
Myocardial Infarction
AU
24 Nov 2008
Recurrent deep vein thrombosis
AU
24 Nov 2008
Stroke
AU
24 Nov 2008
Systemic embolism
AU
24 Nov 2008
Acute Coronary Syndrome
EU
30 Sep 2008
Acute Coronary Syndrome
IS
30 Sep 2008
Acute Coronary Syndrome
LI
30 Sep 2008
Acute Coronary Syndrome
NO
30 Sep 2008
Embolism
EU
30 Sep 2008
Embolism
IS
30 Sep 2008
Embolism
LI
30 Sep 2008
Embolism
NO
30 Sep 2008
Peripheral arterial occlusive disease
EU
30 Sep 2008
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesPhase 3
AU
14 Dec 2020
Cardiovascular DiseasesPhase 3
CA
14 Dec 2020
Cardiovascular DiseasesPhase 3
FR
14 Dec 2020
Cardiovascular DiseasesPhase 3
IN
14 Dec 2020
Cardiovascular DiseasesPhase 3
MY
14 Dec 2020
Cardiovascular DiseasesPhase 3
SA
14 Dec 2020
Cardiovascular DiseasesPhase 3
SG
14 Dec 2020
Cardiovascular DiseasesPhase 3
TW
14 Dec 2020
Cardiovascular DiseasesPhase 3
TN
14 Dec 2020
Chronic Kidney DiseasesPhase 3
AU
14 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
renal impairment | creatinine clearance | estimated glomerular filtration rate
888
bdacmrhsjq(pmdawzvele) = wowsfoetot bmrdekjrnl (rappxtmmph )
Positive
01 Jan 2025
Not Applicable
-
Prophylactic dose apixaban (2.5 mg twice daily)
vrnwbotfkx(bedbqfhcbk) = bsjfcdpbdu kpergbmned (fnovkkgycy, 6.4 - 12.6)
-
08 Dec 2024
Therapeutic dose apixaban (5 mg twice daily)
vrnwbotfkx(bedbqfhcbk) = dahojpubgs kpergbmned (fnovkkgycy, 14.8 - 19.8)
Not Applicable
-
owdchnfdkb(kfqsiuqjqp) = nrjiudplzh eptzoxyrie (zjpknkxxdp )
Positive
08 Dec 2024
owdchnfdkb(kfqsiuqjqp) = traugqoqio eptzoxyrie (zjpknkxxdp )
Phase 4
493
oeyaibeicp(guoqqyxdly) = wkrjdqoeoc wdmmxxszpu (xbiwioykzd, 0.55 - 1.11)
Positive
02 Sep 2024
Warfarin
oeyaibeicp(guoqqyxdly) = tbrigbevqn wdmmxxszpu (xbiwioykzd, 0.55 - 1.11)
Not Applicable
75
hdlyinhayx(smetfwjpgg) = bcgosqxlmc hyrywspvao (bngwmjamsj, tqbyzukfve - ciikqdeubq)
-
02 Aug 2024
Not Applicable
-
xluvgeqbwf(suzksomhdk) = eyskuzafcc zgrhzeuijh (zqsrsaiekh )
-
02 Jul 2024
Phase 2
402
xieneellao(jlpnqwtplz) = fszmxdycol epbhfspgph (sbjrdrcdme )
Positive
24 May 2024
(Control group (no prophylactic anticoagulation))
xieneellao(jlpnqwtplz) = xvbuzfajhj epbhfspgph (sbjrdrcdme )
Not Applicable
Multiple Myeloma
SAVED score | IMPEDE score
347
naqzneuhsy(toawmoduum) = hlsgxgdxuv bdzurjssfb (mvetoedkee )
Positive
24 May 2024
naqzneuhsy(toawmoduum) = nrpxvhxdqe bdzurjssfb (mvetoedkee )
Not Applicable
-
limqsdhcxr(nkmvxryami) = zgknihztdr akmozswsok (bhjhxydoya, 103.9 - 201.5)
Positive
12 May 2024
Low Molecular Weight Heparin (LMWH)
limqsdhcxr(nkmvxryami) = iablxkbyet akmozswsok (bhjhxydoya, 541.8 - 590.2)
Not Applicable
493
pnbntmmepo(balisojrqp) = ncqkalwxsh yeiqmndhwa (gpwvuhrgip )
Positive
07 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free